Literature DB >> 16788689

Prevalence of complications in children with chronic kidney disease according to KDOQI.

H Wong1, K Mylrea, J Feber, A Drukker, G Filler.   

Abstract

The Kidney Disease Outcome and Quality Initiative (KDOQI) Group recommended guidelines for the monitoring and treatment of chronic kidney disease (CKD) in 2002. These recommendations were based on the prevalence of known complications as seen in adults. In children, the exact prevalence of these complications is unknown. We therefore conducted a cross-sectional study of 366 patients with CKD in a single center to analyze the prevalence of these complications across all stages of kidney disease. Patients were categorized to their KDOQI stage of CKD according to their estimated renal function as determined from serum cystatin C. Fifty seven percent of patients had CKD stage 1, 29.0% stage 2, 10.4% stage 3 and 4.1% stages 4+5. Uropathies (31%) were the most prevalent causes of CKD. Glomerular disease accounted for 27%. The overall prevalence of complications was as follows: hypertension 70.2%, anemia 36.6%, proteinuria 11.5%, and metabolic bone disease 16.9%. Metabolic bone disease and anemia occurred frequently, even with a glomerular filtration rate >60 ml/min/1.73 m2. Growth failure (11.5%) was also common and is not a component of the KDOQI guidelines for CKD in children. The prevalence of all complications increased with worsening stage of kidney disease (all P-values significant). In summary, this study supports the KDOQI guidelines in defining and staging CKD in children. This study also highlights the differences in the causes and complications that occur in CKD between adults and pediatrics. We recommend modification of the KDOQI guidelines for children to reflect the differences described in this paper.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16788689     DOI: 10.1038/sj.ki.5001608

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  51 in total

1.  High prevalence of elevated lead levels in pediatric dialysis patients.

Authors:  Guido Filler; Elizabeth Roach; Abeer Yasin; Ajay P Sharma; Peter G Blake; Liju Yang
Journal:  Pediatr Nephrol       Date:  2012-04-17       Impact factor: 3.714

2.  Why multidisciplinary clinics should be the standard for treating chronic kidney disease.

Authors:  Guido Filler; Steven E Lipshultz
Journal:  Pediatr Nephrol       Date:  2012-07-04       Impact factor: 3.714

3.  Treatment of infant formula with patiromer dose dependently decreases potassium concentration.

Authors:  Neil J Paloian; Barbara Bowman; Sharon M Bartosh
Journal:  Pediatr Nephrol       Date:  2019-04-08       Impact factor: 3.714

4.  Pauci-immune glomerulonephritis in children: a clinicopathologic study of 21 patients.

Authors:  Mazdak A Khalighi; Shihtien Wang; Kammi J Henriksen; Margret Bock; Mahima Keswani; Anthony Chang; Shane M Meehan
Journal:  Pediatr Nephrol       Date:  2015-02-12       Impact factor: 3.714

5.  Short stature in advanced pediatric CKD is associated with faster time to reduced kidney function after transplant.

Authors:  Yijun Li; Larry A Greenbaum; Bradley A Warady; Susan L Furth; Derek K Ng
Journal:  Pediatr Nephrol       Date:  2019-01-09       Impact factor: 3.714

Review 6.  Proteinuria and progression of pediatric chronic kidney disease: lessons from recent clinical studies.

Authors:  Sahar A Fathallah-Shaykh
Journal:  Pediatr Nephrol       Date:  2016-06-27       Impact factor: 3.714

7.  Renal formulas pretreated with medications alters the nutrient profile.

Authors:  Jacob M Taylor; Leah Oladitan; Susan Carlson; Jill M Hamilton-Reeves
Journal:  Pediatr Nephrol       Date:  2015-05-01       Impact factor: 3.714

8.  Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay.

Authors:  Rachel Gavish; Salmas Watad; Nathalie Ben-Califa; Ori Jacob Goldberg; Orly Haskin; Miriam Davidovits; Gili Koren; Yafa Falush; Drorit Neumann; Irit Krause
Journal:  Pediatr Nephrol       Date:  2018-07-20       Impact factor: 3.714

9.  Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study.

Authors:  Craig S Wong; Christopher B Pierce; Stephen R Cole; Bradley A Warady; Robert H K Mak; Nadine M Benador; Fredrick Kaskel; Susan L Furth; George J Schwartz
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 8.237

10.  Randomized, double-blind, controlled study of losartan in children with proteinuria.

Authors:  Nicholas J A Webb; Chun Lam; Tom Loeys; Shahnaz Shahinfar; Juergen Strehlau; Thomas G Wells; Emanuela Santoro; Denise Manas; Gilbert W Gleim
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-14       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.